Evidence map›Paper›PMID 33671700›Full record

ArticleViruses2021

Next Generation Sequencing for HIV-1 Drug Resistance Testing-A Special Issue Walkthrough.

Rami Kantor

Abstract readEditorial
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Rami KantorDivision of Infectious Diseases, Alpert Medical School, Brown University, Providence, RI 02906, USA.ORCID 0000-0003-3659-1108

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescentsR01AI147333 · NIAID · MIRIAM HOSPITAL · PI KANTOR, RAMI, VREEMAN, RACHEL CHRISTINE · 2019 to 2024
$3.9M
Real Time Phylogeny and Contact Tracing to Disrupt HIV TransmissionR01AI136058 · NIAID · MIRIAM HOSPITAL · PI KANTOR, RAMI · 2018 to 2022
$3.4M
HIV Treatment Failure and Drug Resistance in Western Kenyan ChildrenR01AI120792 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI KANTOR, RAMI, VREEMAN, RACHEL CHRISTINE · 2016 to 2019
$2.9M
Real Time Phylogeny and Contact Tracing to Disrupt HIV TransmissionR37AI136058 · NIAID · MIRIAM HOSPITAL · PI Rami Kantor · 2025 to 2026
$1.5M
HIV Drug Resistance, Monitoring and TransmissionK24AI134359 · NIAID · MIRIAM HOSPITAL · PI Rami Kantor · 2018 to 2026
$1.3M
NIAID NIH HHS K24 AI134359NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI120792NIAID NIH HHS R01 AI147333NIAID NIH HHS R37 AI136058
6 · The paper itself

Abstract

Drug resistance remains a global challenge in the fight against the HIV pandemic [...].

Indexed as

Drug Resistance, ViralAnti-HIV AgentsHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansAnti-HIV Agents

Identifiers

PMID33671700
PMCPMC7926934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.